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Abstract
With the advent of subgenomic hepatitis C virus (HCV) replicons, studies of the intracellular steps of the viral replication
cycle became possible. These RNAs are capable of self-amplification in cultured human hepatoma cells, but save for the
genotype 2a isolate JFH-1, efficient replication of these HCV RNAs requires replication enhancing mutations (REMs),
previously also called cell culture adaptive mutations. These mutations cluster primarily in the central region of non-
structural protein 5A (NS5A), but may also reside in the NS3 helicase domain or at a distinct position in NS4B. Most efficient
replication has been achieved by combining REMs residing in NS3 with distinct REMs located in NS4B or NS5A. However, in
spite of efficient replication of HCV genomes containing such mutations, they do not support production of infectious virus
particles. By using the genotype 1b isolate Con1, in this study we show that REMs interfere with HCV assembly. Strongest
impairment of virus formation was found with REMs located in the NS3 helicase (E1202G and T1280I) as well as NS5A
(S2204R), whereas a highly adaptive REM in NS4B still allowed virus production although relative levels of core release were
also reduced. We also show that cells transfected with the Con1 wild type genome or the genome containing the REM in
NS4B release HCV particles that are infectious both in cell culture and in vivo. Our data provide an explanation for the in vitro
and in vivo attenuation of cell culture adapted HCV genomes and may open new avenues for the development of fully
competent culture systems covering the therapeutically most relevant HCV genotypes.
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Introduction
HCV is a positive strand RNA virus which belongs to the family
Flaviviridae [1]. Its genome of about 9.6 kb is composed of the
59non-translated region (NTR), an open reading frame encoding a
large polyprotein, and the 39NTR [2] (Fig. 1A). In the N-terminal
region, the polyprotein is processed by cellular proteases to yield
the structural proteins Core (C), envelope proteins 1 and 2 (E1,
E2), and p7. Cleavage of the non-structural (NS) proteins is
accomplished by NS2 at the NS2/3 site and by the NS3 protease
at all remaining sites [2]. NS4B induces cellular membrane
alterations thought to provide a scaffold for the viral replication
machinery [3,4]. NS5B is the viral RNA-dependent RNA
polymerase whereas NS5A is an RNA binding phosphoprotein
involved in RNA replication and virus assembly [5–8]. Two NS5A
phospho variants have been described assumed to correspond to a
basal and a hyper phosphorylated form (p56 and p58, respectively)
[9]. Phosphorylation of NS5A appears to be mediated by casein
kinase I and II [7,10]. Interestingly, interference with NS5A
hyperphosphorylation by inhibitors of casein kinase I such as
H479 enhances viral RNA replication by more than 10-fold
arguing that this modification is of disadvantage for high level
replication [11].
About 170 million people are chronically infected with HCV.
At present, neither a selective antiviral therapy nor a vaccine is
available, and only a fraction of patients treated with a
combination of polyethylene glycol (PEG)-conjugated interferon
alpha (IFN-a) and ribavirin can be cured [12]. Thus, there is an
urgent need for more effective antiviral treatment that also has
fewer side effects. The development of such therapeutics and
vaccines has long been hampered by the notoriously poor
replication of HCV in cultured cells. The advent of subgenomic
replicons that were originally derived from the genotype 1b isolate
Con1 and that amplify efficiently in the human hepatoma cell line
Huh-7 has in part overcome this limitation [13]. However, for
Con1 mutations within the viral NS proteins are required to
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analyses [14–17]. These mutations have originally been designated
‘cell culture adaptive mutations’, but should be renamed as
‘replication enhancing mutations’ (REMs) in order to discriminate
them from cell culture adaptive mutations that increase virus titers
without affecting replication [18–23]. The latter will therefore be
designated ‘titer enhancing mutations’ (TEMs) throughout this
report. REMs have been identified with all replicons derived from
genotype 1 HCV isolates (reviewed in [24]). These mutations
cluster primarily in the center of NS5A and at distinct positions in
NS3 and NS4B. Certain combinations of mutations enhance RNA
replication cooperatively, the exact mode of action, however,
remains elusive.
The superior RNA replication capacity accomplished by
adapted NS-proteins allowed the generation of efficiently repli-
cating full length HCV genomes [25,26]. However, in spite of high
level replication, these genomes do not or only very poorly support
the production of detectable levels of infectious HCV particles
[25,26]. Earlier we demonstrated that the presence of certain
REMs interferes with infectivity in vivo [27]. A Con1 genome with
a single mutation in NS5A (S2197P) was severely attenuated in
chimpanzees inoculated intrahepatically with in vitro transcripts of
this genome. A triple mutant carrying two mutations in NS3
(E1202G, T1280I) and the aforementioned substitution in NS5A
was unable to establish a productive infection implying that REMs
interfere with infectivity in vivo. In line with this assumption,
efficient production of infectious HCV in cell culture so far has
only been achieved with a genotype 2a HCV isolate (designated
JFH-1) that replicates to very high levels without requiring REMs
[28,29].
Employing transient replication and virus release assays in this
study we demonstrate that REMs interfere with the production of
infectious HCV particles. We show that at least in case of the
Con1 isolate, mutations especially in the NS3 helicase, but also in
NS5A and NS5B lead to strong impairment of virus production
whereas Huh-7 cells transfected with the wild type genome or a
genome containing one REM in NS4B release substantial amounts
of HCV that is infectious in cell culture and in vivo.
Results
Interference of REMs with virus production
Given the infectivity of the wild type Con1 HCV isolate in vivo
on one hand and its poor replicative capacity in transfected Huh-7
cells in vitro on the other hand, we first investigated whether this
genome is capable of producing virus particles in cell culture. Four
constructs were used for this experiment: Con1/wild type (wt), a
replication incompetent variant thereof with a mutation that
destroys the active site of the polymerase (Con1/D318N), a weakly
adapted Con1 genome containing a REM in NS5A (Con1/
S2197P) and a highly adapted Con1 genome containing two
REMs in NS3 (E1202T, T1280I) and one in NS5A (S2197P) and
designated Con1/NS3+S2197P (Fig. 1A). We have shown earlier
that the combination of these 3 REMs enhances RNA replication
in a cooperative manner [15] In vitro transcripts were transfected
into Huh-7 cells and RNA replication was quantified by Northern
blotting and phospho imaging (Fig. 1B and C, respectively),
whereas virus production was measured by determining the
release of core protein into the supernatant of transfected cells
(Fig. 1D). As expected Con1/wt replicated poorly in Huh-7 cells,
displaying no clear difference to the replication incompetent
mutant Con1/D318N. In contrast, elevated RNA levels were
observed for the weakly and highly adapted genomes (Con1/
S2197P and Con1/NS3+S2197P, respectively). Analysis of
extracellular core protein levels revealed that highest amounts of
core were transiently released into the supernatant of cells
transfected with Con1/wt (Fig. 1D). Core protein was first
detectable at 12 h post transfection, increased to peak levels at
24 h, and declined rapidly thereafter. This kinetic correlated well
with intracellular RNA levels with highest amounts of Con1/wt
input RNA detected right after transfection followed by a rapid
decline due to the poor replication of this genome (Fig. 1D).
Interestingly, the same kinetic of core release was found with the
replication inactive Con1/D318N mutant demonstrating that at
least in this setting core release does not require RNA replication.
Most importantly, the Con1 variants containing the REMs
displayed clearly impaired core release. This defect was most
prominent for the triple mutant Con1/NS3+S2197P which
despite highest intracellular RNA and core quantities did not
release core protein to detectable levels. Coherently, Con1/
S2197P harbouring a single REM in NS5A exhibited impaired
release of core relative to Con1/wt, although due to the adapted
phenotype, intracellular RNA levels were elevated. In contrast,
about 15% of intracellular core protein was released from cells
transfected with Con1/wt (Fig. 1E). The inverse correlation
between increase of RNA replication by the REMs in NS3 and
NS5A and the impaired core release suggested that such mutations
interfere with virion production.
To more quantitatively determine the correlation between the
extent of replication enhancement by a given REM and the
impairment of virus production we generated a panel of Con1-
derived subgenomic reporter replicons and full length genomes
into which single REMs were inserted. For this purpose we
selected several representative REMs residing in NS3 (E1202G,
T1280I), or NS4B (K1846T), or NS5A (S2197P, S2204R), or
NS5B (R2884G) that increase replication of subgenomic HCV
replicons to various extents (Fig. 2A) [17]. In addition, we
analyzed two different combinations of mutations in which the two
REMs in NS3 were combined either with the REM in NS4B
(construct Con1/NS3+K1846T) or NS5A (construct NS3+
S2197P). As shown in Fig. 2A amongst the single mutations, the
REM located in NS4B (K1846T) enhanced RNA replication most
whereas the two mutations residing in NS3 had least effects
Author Summary
The hepatitis C virus (HCV) is a major cause of acute and
chronic liver disease. Unusual for a positive strand RNA
virus, HCV has the high propensity to establish persistent
infection, which increases the risk for liver cirrhosis and
hepatocellular carcinoma. No selective therapy is available
thus far and its development has been hampered by the
lack of adequate cell culture systems. With the advent of
subgenomic replicons, i.e. RNAs containing only the viral
replicase genes and that self-amplify in the human liver
cell line Huh-7, this hurdle has been overcome to some
extent. However, save for a single genotype 2a isolate,
efficient replication of all HCV isolates described thus far
requires replication enhancing mutations (REMs), but
genomes with REMs do not support production of
infectious virus particles. In this study we show that
except for one mutation in non-structural protein 4B, REMs
interfere with the assembly of infectious virus particles,
whereas an unaltered HCV genome supports production
of cell culture–derived virus that is infectious in vitro and in
vivo. Our observations provide an explanation for the
attenuation of cell culture adapted HCV genomes and
open new perspectives for the development of culture
systems for difficult to treat HCV genotypes.
HCV Particle Production and Infectivity
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combined either with the mutation in NS4B or the S2197P
substitution in NS5A, RNA replication was enhanced coopera-
tively (replicons NS3+K1846T and NS3+S2197P, respectively)
[17].
To determine the impact of these mutations on core release they
were inserted into the parental Con1 full length genome.
Subsequently, mutants were transfected into Huh-7 cells and core
release was determined by ELISA. The results in Fig. 2B show that
strongest inhibition of virus production (assembly or release) was
exerted by either of the two REMs in NS3 that enhanced RNA
replication only to a minor extent. Profound impairment of core
release was mediated by the REMs residing in NS5A or NS5B
whereas the REM in NS4B still allowed core release to a level
comparable with the wild type. However, when this mutation or
the S2197P REM in NS5A was combined with the two mutations
in NS3 core release was potently blocked.
Given the rather efficient core release obtained with the Con1/
K1846T genome, we performed a more detailed quantitative
analysis by measuring the accumulation of intra- and extracellular
core protein amounts at various time points post transfection
(Fig. 2C). In agreement with the elevated replication level, the
Figure 1. Transient replication of HCV Con1-derived constructs in Huh-7 cells and release of core protein from transfected cells. (A)
Schematic representation of transfected RNA genomes. The polyprotein is indicated by an open box, the individual functional proteins are separated
by vertical lines. Non-translated regions are depicted as shaded bars, REMs and the position of the mutation destroying the active site of the NS5B
RdRp (D318N) are specified above the respective positions in the coding region. (B) Transient RNA replication of full length Con1-derived genomes.
Ten mgo fin vitro transcribed RNA of the constructs specified in the top were transfected into Huh-7 cells that were harvested at given time points.
Total cellular RNA was prepared and HCV RNA and beta-actin RNA were detected by Northern hybridization. (C) The amount of HCV RNA was
determined by phospho imaging and is expressed relative to the input determined 4 h post transfection. Values were normalized for equal RNA
loading as determined with the beta-actin specific signal. (D) Time course of accumulation of HCV core in cell culture supernatant of transfected Huh7
cells. Cells were transfected and seeded as described in (A). At given time points, culture medium was harvested, filtered through 0.45 mm pore-size
filters, and analysed for core protein by ELISA. Duplicate measurements, mean value of duplicates and standard errors of the means are given. (E)
Efficiency of core release from cells transfected with Con1/wt or the adapted genome Con1/NS3+S2197P [27]. Amounts of core protein accumulated
intracellularly or in cell culture medium were determined by ELISA and used to calculate the percentage of intracellular core protein released into the
supernatant of transfected cells for each given time point. Mean values of two independent electroporations including standard errors of the means
are shown.
doi:10.1371/journal.ppat.1000475.g001
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cells transfected with Con1/K1846T as compared to Con1/wt
transfected cells, but substantially lower compared to Con1/
NS3+K1846T (Fig. 2C, left panel). Likewise, amounts of core
protein released into the supernatant of transfected cells were
elevated in case of Con1/K1846T transfected cells (middle panel).
However, when correlating the amount of released core protein to
the total amount of core protein expressed we found that also the
NS4B mutation reduced core protein release, especially at later
time points post transfection (48 and 72 h; Fig. 2C, right panel). In
summary, our data suggest that REMs, at least those examined
here, have a negative impact on core release, but the extent of this
interference does not correlate with the extent of RNA replication
enhancement.
Role of envelope glycoproteins for Con1/wt particle
production
To confirm that core protein released into supernatants of cells
transfected with Con1-derived constructs represents virus particles,
we studied the requirements for core release by using reverse
genetics. Several variants of the Con1 genome were generated:
Mutant DE1-E2 comprising a large in frame deletion that
encompasses most of the E1 and E2 coding sequence; mutant
wt/A358Ins and K1846T/A358Ins in which an alanine codon
Figure 2. Impact of REMs on HCV particle release. (A) Replication of subgenomic luciferase replicons in transfected Huh-7 cells. The replication
deficient replicon D318N served as negative control. Values refer to luciferase activities determined 48 h post transfection of Huh-7 cells after
normalization for transfection efficiency determined 4 h post transfection. Data are taken from reference [17]. (B) Huh-7 cells were transfected with
the Con1/wt genome or Con1 genomes carrying REMs specified in the bottom of the graph. The amount of core protein released into the
supernatant 24 h after transfection was determined by using core ELISA and is expressed relative to the quantity of core measured for Con1/wt. Mean
values of between 2 and 11 independent repetitions (depending on the construct) including the standard deviation are given. (C) Impact of REMs in
NS4B and NS3 on RNA replication as determined by intracellular accumulation of core protein (left panel). The kinetic of release of core protein into
the supernatant of Huh-7 cells after transfection with the Con1/wt or the Con1/K1846T or the Con1/NS3+K1846T genome is shown in the middle
panel. The right panel shows the percentage of intracellular core that is released into the culture supernatant of Huh-7 cells at various time points
after transfection with each of the 3 genomes. A representative example of two independent repetitions is shown.
doi:10.1371/journal.ppat.1000475.g002
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mutants wt/NK367AA and K1846T/NK367AA in which two
amino acid residues within the transmembrane domain of E1 were
replaced by alanine residues. The A358Ins and NK367AA
mutations were previously shown to disturb E1/E2 heterodimer-
ization thereby blocking formation of functional glycoprotein
complexes while the deletion of E1-E2 is known to abrogate
release of infectious JFH1 particles [28,30,31]. Twenty four hours
after transfection, total amount of core protein present in cell
lysate and medium was determined by core-specific ELISA. Con1
wild type genomes expressed comparable amounts of core in the
cell lysate arguing for comparable transfection efficiency (Fig. 3A).
Owing to higher replication, core amounts in cells transfected with
the K1846T-constructs were higher. In case of the wild type up to
about 45% of intracellular core protein was released, whereas in
case of the K1846 mutant this value was reduced to about 20%
(Fig. 3C). Most importantly, core release was reduced to
background levels (as determined with the DE1/E2 mutant)
whenever the mutations in the envelope coding sequence were
introduced and this effect was found both with the wt and the
K1846T genome (Fig. 3C). This result indicates that core release
observed with these two genomes is a specific process that requires
functional envelope glycoproteins.
If authentic virus particles were produced from Con1/wt or
Con1/K1846T transfected cells, the core protein shell which
harbours the viral RNA should be surrounded by a lipid
membrane containing the viral envelope glycoproteins. Conse-
quently, core protein and HCV RNA should be captured by
antibodies directed against E1 or E2. To identify HCV-envelope
specific antibodies to be used for Con1 virus capture assay we first
screened a panel of human monoclonal antibodies recognizing
HCV E2 or E1 proteins for their capacity to bind to HCV pseudo
particles (HCVpp) generated in 293T cells by using an HIV-based
vector and a HCV Con1 E1–E2 expression construct. The
isotype-matched RO4 antibody which is directed against p64 of
Cytomegalovirus (CMV) served as negative control. Upon
incubation with monoclonal antibodies the amount of captured
HCVpp was determined by using HIV p24-specific ELISA. As
shown in Fig. 4A, highest yields were obtained with the human
monoclonal antibodies CBH-5, CBH-8C and CBH-2 [32]. For
subsequent capture assays we used CBH-5 and CBH-2, two
efficient capture antibodies as well as CBH-7 that captured only
low amounts of Con1-derived HCVpp and thus served as
sensitivity control. The RO4 antibody was used as negative
control. Concentrated cell culture supernatants derived from
Con1/wt, Con1/K1846T and Con1/DE1/E2 transfected Huh-7
cells were incubated with antibody coupled beads and the quantity
of captured HCV RNA was determined by qRT-PCR after
extensive washing with PBS (Fig. 4B). Although the overall capture
efficiency was only about 5%, particles present in supernatant of
Con1/wt and Con1/K1846T transfected cells could specifically
be captured with all 3 CBH-antibodies. Capture efficiency
Figure 3. Release of HCV core into the supernatant of
transfected cells depends on the expression of functional
glycoproteins. Ten mgo fin vitro transcribed RNA of the constructs
specified below each bar were transfected into Huh-7 cells and 24 h
later culture medium was harvested and filtered, whereas cells were
lysed with 1% Triton X-100 in PBS. The total amount of HCV core in the
cell lysate (A) and culture supernatant (B) was determined by ELISA. (C)
Relative core release expressed as the fraction (in %) of total
intracellular core protein that is released into the culture fluid. Mean
values of two independent electroporations including the standard
error of the means are given.
doi:10.1371/journal.ppat.1000475.g003
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background amounts of RNA were captured from the supernatant
with the non-specific antibody (RO4) or from supernatant of
Con1/DE1-E2 transfected cells demonstrating specificity of this
capture assay.
Biophysial characterization of Con1-derived particles
Biophysical properties of captured particles were further
characterized by treatment with S7 micrococcal nuclease under
various conditions. Assuming that intact particles protect the viral
genome, we treated captured complexes with nuclease without or
with prior treatment with the detergent Triton X-100 (Fig. 4C).
We found that the viral genome in captured complexes was
resistant to nuclease treatment consistent with the protection of the
RNA by an intact virus particle. Removal of lipids however, by
detergent treatment rendered the viral genome fully nuclease
sensitive and RNA levels after Triton X-100 and S7 treatment
were at the background as determined with the capture with the
R04 control antibody. Addition, of protease to the detergent-
treated particles did not increase nuclease sensitivity (not shown).
These results suggested that HCV nucleocapsids –if they are
formed at all- might be unstable after removal of the envelope
and/or the lipoprotein shell.
Densities of Con1-derived particles were determined by using
density gradient centrifugation in comparison to virus particles
produced from JFH-1 transfected Huh-7 cells and virus particles
contained in a high titer patient serum. Gradient fractions were
harvested from the top and core protein amounts contained in
each fraction were determined by ELISA. We did not use qRT-
PCR because of residual amounts of in vitro transcripts and plasmid
DNA in virus preparations generated by RNA transfection
precluding unambiguous measurements of particle associated
HCV RNA. In the first set of experiments we compared particles
derived from Con1/wt, JFH-1 and patient serum (Fig. 5A). Most
particles present in patient serum had a density of about 1.04 g/ml
probably representing viruses associated with very low density and
low density lipoproteins [33–36]. The minor peak with a density of
ca. 1.12 g/ml may correspond to virus that is less complexed with
Figure 4. Capture of Con1 particles by E2-specific antibodies and characterization of captured particles. (A) Identification of
monoclonal antibodies reacting with Con1 envelope glycoproteins. HCVpp carrying Con1 envelope glycoproteins were incubated with immobilized
antibodies specified in the bottom and captured particles were quantitated by using p24-specific ELISA. Numbers above each bar refer to fold
increase above background as determined by capture assay with an irrelavant antibody (RO4). Mean values of three experiments and the standard
deviations are given. (B) Capture of HCV particles from supernatants of Huh-7 cells transfected with Con1/wt or Con1/K1846T or the Con1 mutant
lacking most of the envelope glycoprotein coding region (DE1–E2). Bound particles were quantified by using TaqMan qRT-PCR. Mean values of
triplicate measurements including the standard error of the means are given. (C) Characterization of captured Con1/wt particles by nuclease
treatment. Concentrated culture supernatant of Con1/wt transfected cells was used for capture with control antibody R04 (right bar) or CBH-5 (all
other bars). Immune complexes obtained with the latter were split into 4 aliquots that were left untreated or treated with 0.5% Triton X-100, or
nuclease S7, or 0.5% Triton X-100 and S7 nuclease. RNA was extracted and quantified by TaqMan qRT-PCR.
doi:10.1371/journal.ppat.1000475.g004
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1 particles exhibited an analogous density profile but with very
different ratios when compared to the patient-derived particles.
Most particles had a density of 1.14 g/ml, whereas only a minor
and broad peak was found at very low density in the range of 1.03
to 1.08 g/ml. In this respect, density profiles of Con1/wt and JFH-
1 derived virus particles were indistinguishable. Likewise, density
profiles of Con1/wt and Con1/K1846T derived particles were
also very similar (Fig. 5B) arguing that the genome with this REM
in NS4B is capable of producing virus particles, too.
In summary, the similarity of buoyant densities of cell culture-
derived Con1/wt, Con1/K1846T and patient-derived particles
supported the notion that authentic HC virions were released from
Huh-7 cells transfected with these HCV genomes. The different
relative amounts of particles at very low and high densities may
reflect differences of lipoprotein ‘imprinting’ of the particles by the
host cell (Huh-7 cells versus fully differentiated human hepato-
cytes) in agreement with the reported defect of Huh-7 cells to
produce vLDL [37].
Infectivity of Con1/wt particles in cell culture
Attempts to directly demonstrate infectivity of Con1/wt or
Con1/K1846T derived particles in cell culture were complicated
by the low replicative capacity of both genomes. However,
recently Neddermann and colleagues demonstrated that inhibition
of casein kinase I that appears to be responsible for hyperpho-
sphorylation of NS5A, with compound H479 results in substantial
enhancement of RNA replication of a non-adapted genome
whereas replication of a genome containing a REM in NS5A was
blocked [10,11,38]. Assuming that enhancing replication of
Con1/wt and possibly also Con1/K1846T with H479 would
facilitate detection of viral proteins in infected cells, we first
established the optimal concentration of this kinase inhibitor
required to stimulate replication of Con1/wt and Con1/K1846T
in Huh7.5 cells. In agreement with the report by Neddermann and
colleagues [11] we observed an about 5-fold increase of replication
of Con1/wt at 48 h post transfection when Huh7.5 cells were
treated with 10 mM of H479 whereas replication of Con1/
K1846T was not enhanced (Fig. 6A). Nevertheless, even under
optimal conditions replication was about 10–100-fold below the
level achieved with the highly cell culture adapted replicon Con1/
NS3+K1846T (data not shown).
Having established the optimal conditions for H479-mediated
enhancement of Con1/wt replication, we exploited this protocol to
determine infectivity of HCV particles in tissue culture (Fig. 6B).
Huh7.5 cells, which are more permissive for HCV infection than
Huh7-Lunet cells [39] were inoculated with about 200 Con1/wt
or Con1/K1846T particles per cell (calculated according to the
amount of core protein and assuming 200 core protein molecules
per particle) or the analogous volume of concentrated supernatant
of mock-transfected cells that was prepared in parallel. Cells
inoculated with Con1/wt virus or mock-supernatant were treated
with H479 whereas Con1/K1846T inoculated cells were left
untreated. Three days after inoculation, cells were fixed and the
replicase component NS5A was detected by immunofluorescence.
As shown in Fig. 6C, under all conditions no NS5A-specific signal
could be detected in cells inoculated with the control-supernatant.
In contrast, a low but specific signal was found in Con1/wt
inoculated cells and this signal was enhanced in cells that had been
treated with the kinase inhibitor H479. Likewise, NS3 and NS5A
expression was detected in a few cells inoculated with Con1/
K1846T containing supernatant (Fig. 6D). Infection appeared to
be a specific process because no signal was detected in Con1/wt
inoculated cells that had been treated with Concanamycin A,
which is an inhibitor of endosomal acidification and that was
shown to block infection of Huh-7 cells with JFH-1 derived virus
[40] (Fig. 6C). Infection was also not detected upon infection of
Huh7-Lunet cells that express low amounts of CD81 (not shown).
These results suggested that cell culture produced Con1/wt or
Figure 5. Density profiles of HCV particles derived from Con1/
wt, Con1/K1846T, JFH-1 and patient serum. (A) Approximately
22 ml of filtered cell culture fluid harvested 24 h after transfection of
Huh-7 cells with Con1/wt RNA were concentrated via ultracentrifuga-
tion over a 60% iodixanol cushion. In case of JFH-1 approximately 26 ml
supernatant harvested 96 h post transfection and concentrated in the
same manner were used. The concentrates were overlaid with a linear
iodixanol gradient (0%–60%) and spun for 20 h at 110,000 g at 4uC. In a
similar experiment, 0.5 ml of high titer patient serum was resolved in an
iodixanol density gradient. Twelve fractions a ` 1ml were harvested from
the top, and the amount of HCV core protein contained in each fraction
was determined by Trak C ELISA, respectively. HCV core content per
fraction is plotted against the density of the respective fraction. (B)
Result of an analogous experiment but using culture supernatant of
Huh-7 cells after transfection with Con1/wt or Con1/K1846T.
doi:10.1371/journal.ppat.1000475.g005
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tative analyses could not be performed due to the low replication
of these genomes.
In vivo infectivity of Con1/wt and Con1/K1846T particles
produced in cell culture
To firmly demonstrate infectivity of cell culture-produced
Con1/wt and Con1/K1846T particles, we performed in vivo
infection experiments. UPA+/+-SCID mice that had been
xenografted with primary human hepatocytes, were inoculated
with equally concentrated culture supernatants from Huh7 cells
that had been transfected with Con1/wt or Con1/K1846T. As
control we used supernatants from cells transfected with Con1/
NS3+K1846T, which supports core release to only very low level.
Final concentrations of HCV RNA in the purified and
concentrated stocks were about 2610
9 RNA copies (IU) per ml
for all 3 preparations. Based on core-ELISA measurements this
corresponded to 5.4610
3 pg per ml of Con1/wt, 2610
3 pg/ml of
Con1/K1846T and 2.3610
2 pg per ml core protein of Con1/
NS3+K1846T, respectively. Assuming that one HCV particle
contains about 200 copies of core protein (an estimate that is
derived from hepatitis B virus, which has a similar particle size
[41]), the (theoretical) infection dose per animal (100 ml inoculum)
was about 7.7610
7 particles in case of Con1/wt, 2.9610
7 particles
in case of Con1/K1846T and about 3610
6 particles in case of
Con1/NS3+K1846T, respectively. The comparable amounts of
RNA detected in all 3 preparations argues that in case of the triple
mutant RNA-containing replication complexes that contain no or
very low amounts of core protein were released [25].
For each construct, two mice were inoculated with 100 ml of the
concentrated stock and virus titers in serum were determined by
qRT-PCR (Fig. 7). Unfortunately, one mouse inoculated with
Con1/K1846T died spontaneously already at week 2 while the
second mouse died at week 6, presumably a follow-up reaction of
serum withdrawal. The time course of infection shown in Fig. 7
demonstrates that mice inoculated with Con1/wt or Con1/
K1846T particles were readily infected and remained viremic
throughout the observation period. In case of the wild type, peak
viremia was observed at week 3 post inoculation and steadily
declined thereafter, most likely due to a decreased survival of the
Figure 6. In vitro infectivity of Con1/wt particles released from transfected Huh7.5 cells. (A) Enhancement of HCV RNA replication by
kinase inhibitor H479. Subgenomic Con1 luciferase replicons were transfected into Huh7.5 cells that were seeded into medium containing H479 at
concentrations specified in the right. Cell lysates were prepared at 4 h and 48 h after transfection and luciferase activities were determined. The
replication defective replicon Con1/D318N served as negative control. Cells treated with DMSO only were used as reference. For each construct,
values were normalized to the luciferase activity of the respective DMSO control in order to determine the fold induction or reduction of replication.
Data (mean6S.D.; n=3) were analyzed using two-way ANOVA test. (B) Experimental approach used to detect in vitro infectivity of Con1 virus. (C)
Immunofluorescence analysis of Huh7.5 cells 72 h after inoculation with supernatant from cells transfected with the Con1/wt genome (upper panels)
or mock transfected cells (lower panels). Cells were treated either with DMSO only (Mock; left panels), or with H479 (middle panels) or with H479 and
ConcanamycinA (right panels) as specified in panel (B). Cells were fixed 72 h after inoculation and NS5A was detected by immunofluorescence
microscopy. (D) Detection of NS3 and NS5A expression in Huh7.5 cells inoculated with cell-free concentrated supernatant containing Con1/K1846T
particles. Cells were fixed 48 h after inoculation and processed for indirect immunofluorescence. Nuclei were counterstained with DAPI.
doi:10.1371/journal.ppat.1000475.g006
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supernatants from Con1/NS3+K1846T transfected cells remained
negative and viral RNA was not detected in any of the serum
samples. The fact that already one week post inoculation these
animals were RNA negative also shows that input virus did not
interfere with the read-out. The mouse inoculated with Con1/
K1846T virus also was readily infected and viremia was well
detectable in all available serum samples.
To confirm that the viral genome in the mouse inoculated with
the Con1/K1846T mutant had not reverted to wild type, the
serum sample obtained at week 6 post inoculation was used for
cloning of a genome fragment covering the NS4B coding region.
Sequence analysis confirmed that the HCV genome in this mouse
had retained this particular mutation (data not shown). In
summary, these results convincingly demonstrate that Con1/wt
and Con1/K1846T transfected Huh-7 cells release infectious
HCV particles. Their production is blocked by various REMs,
most notably those residing in the NS3 helicase. Thus, save for the
single substitution in NS4B tested here, mutations that enhance
RNA replication interfere with virus assembly.
Discussion
Production of infectious HCV in cell culture so far is only
possible with the genotype 2a isolate JFH-1 which replicates to
very high levels without requiring REMs. In contrast, all genotype
1 isolates described until now replicate very poorly and need
enhancing mutations. As shown in this report, at least in the
context of Con1, but probably also for other genotype 1 isolates,
with the exception of the K1846T substitution in NS4B REMs
interfere with virus production. This is an important finding for
two reasons: First, these results support earlier assumptions that
REMs augment RNA-replication via different mechanisms [17].
While most of the mutations we analyzed more or less completely
abolished virus production, the K1846T mutation in NS4B
elevated RNA replication but interfered with virus formation only
to a minor extent. These results clearly point to qualitative
differences in the mode by which REMs modulate RNA
replication and (in)-directly virus production.
Second, these data clarify why Huh-7 cells transfected with
genomes containing REMs [25,26] failed to produce virus
particles. It is not due to unfavourable host cell conditions like
the lack of assembly factors, but rather a consequence of these
mutations especially those in NS3 that interfere with virus
production, most likely particle assembly. These data therefore
explain the attenuation of adapted Con1 genomes in vivo [27]. In
fact, in an earlier study we had shown that a Con1 genome
containing the three adaptive mutations of the Con1/
NS3+S2197P construct (E1202G and T1280I in the helicase
and S2197P in NS5A) was unable to establish an infection upon
intrahepatic inoculation of a chimpanzee. A Con1 genome with
only the NS5A mutation (S2197P) was attenuated and rapidly
reverted to wild type. Taking the data from the present study into
account, we can assume that these genomes replicated in RNA-
inoculated hepatocytes of the chimpanzee, but due to impaired
assembly progeny virus was not produced by Con1/NS3+S2197P
and therefore the infection was abortive. Since the Con1/S2197P
mutant still releases core protein (virus), albeit to very low levels,
initial virus spread in the animal most likely was very limited until
the mutant had reverted to wild type.
We note that REMs have also been described extensively for the
genotype 1a isolate H77 [16]. These mutations reside primarily in
the center of NS5A, but cooperative mutations have also been
found in the helicase [42]. Although initial attempts to produce
infectious H77 virus in cell culture failed with genomes carrying
these mutations [42], a highly adapted genome containing 5
REMs has been described recently that replicates to levels
comparable to JFH-1 [43,44]. Most notably, cells transfected with
this H77-S genome release infectious virus particles, but the
amounts are very low. Moreover, the specific infectivity calculated
as the ratio of HCV RNA molecules (genomes) per infectious unit
was about 400-fold lower as compared to JFH-1 (5.4610e4 vs.
1.4610e2, respectively) [44]. The reason why H77-S transfected
cells release such high amounts of HCV RNA is unclear.
However, the low buoyant density of the RNA in density gradients
and the presence of NS3 and NS5B in these fractions suggest that
replication complexes possibly released from dying cells due to
cytotoxicity of the efficiently replicating H77-S genome may in
part account for these high RNA copy numbers in culture
supernatants.
Owing to poor replication, infectivity assays of Con1/wt and
Con1/K1846T viruses were extremely difficult. Although repli-
cation of the wild type genome could be stimulated with the kinase
inhibitor H479, only a very low number of NS5A positive cells
became detectable. In case of the Con1/K1846T genome,
intrinsic replication efficiency of this genome was still too low for
unambiguous detection of viral RNA or proteins. Inclusion of
additional REMs either reduced RNA replication (in case of
REMs residing in NS5A) [17] or blocked core release (in case of
REMs residing in NS3). Furthermore, treatment of Con1/
K1846T transfected cells with the kinase inhibitor H479 reduced
rather than enhanced RNA replication, comparable to what has
been described for REMs residing in NS5A [11]. Finally, attempts
to adapt Con1/wt or Con1/K1846T genomes to continuous Huh-
Figure 7. In vivo infectivity of Con1/wt, Con1/K1846T and Con1/
NS3+K1846T genomes in uPA-SCID mice. Huh7-Lunet cells were
transfected with either of these constructs, supernatants were collected
12 and 24 h post transfection, pooled for each construct and used for
virus purification and concentration as described in Materials and
Methods. Two mice were each inoculated with 2610
8 IU HCV RNA per
mouse and construct (100 ml inoculum size) and viral RNA loads in sera
were determined at the indicated time points after inoculation by qRT-
PCR. In case of Con1/K1846T inoculated mice, one died at week 2 (not
shown) and the second shortly after week 6. While sera of Con1/wt and
Con1/K1846T inoculated mice contained high viral loads already in the
first blood sample, Con1/NS3+K1846T-inoculated mice remained HCV
RNA negative throughout the 10 weeks observation period.
doi:10.1371/journal.ppat.1000475.g007
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in passaged cells or culture supernatants, due to insufficient
replication capacity (V.L. and R.B., unpublished).
Although the underlying mechanism interfering with virus
assembly is unclear, our result argues for a cross-talk between
structural and non-structural proteins during the assembly process.
In fact, several TEMs have recently been described in the context of
JFH-1 and various JFH-1-based infectious chimeras. These
mutations reside in the region encoding core to NS2, but very
often in the NS3 helicase domain and the RNA binding replicase
factorNS5A [18–22,45–47]. The mutations stimulate production of
infectious virus particles without major effects on RNA replication
arguing that the viral NS proteins modulate the efficiency of virus
production [18]. In fact, we and others have recently shown that
NS5A playsa verycriticalroleintheassemblyprocess,whichoccurs
in close proximity of lipid droplets [6,7,48–50]. Core protein
accumulatesonthesurfaceoftheseorganellesand appearstorecruit
NS5A or the replicase complex to these sites to trigger virus
assembly [48]. It was also found that alterations of NS5A
phosphorylation, for which casein kinase I appears to play a major
role [10,38], have a strong impact on NS5A – core interaction and
virus assembly [7,8] and that most, if not all, REMs reduce NS5A
hyperphosphorylation [16,51,52]. Finally, pharmacological inhibi-
tion of NS5A hyperphosphorylation enhances RNA replication as is
the case with REMs [11]. The current model of HCVassembly that
emerges from these observations assumes that via its domain 2 core
protein efficiently localizes to lipid droplets [53] whereas NS5A is
primarily a component of the replicase complex. We speculate that
depending on its phosphorylation status, NS5A is recruited to lipid
dropletstointeractwiththe core proteininawaythattheviralRNA
genome is transferred to core, thus triggering virus assembly. In this
respect REMs described here may interfere with the interaction
between NS5A and core or recruitment of NS5A to lipid droplets or
the RNA transfer from the replicase (helicase, NS5A) to the core
protein thereby attenuating virus production. The fact that most
REMsenhanceRNAreplicationcouldthereforebeduetoretention
of the viral RNA within the replication complex at the expense of
RNA transfer to lipid droplets and/or RNA delivery to the core
protein. In this context it is important to note that enhanced
replication itself is not responsible for the interference with virus
assembly since an adapted Con1 genome with an inactive NS5B
polymerase still does not support virus production (data not shown)
whereas the analogous replication deficient genome lacking REMs
does (Fig. 1D). Moreover, JFH-1/wt supports assembly in spite of
highly efficient RNA replication. Therefore, we hypothesize that
REMs may arrest the viral RNA in a state that prevents the
assembly process. The low-level release of virus from H77-S
transfected cells may be due to an alternative assembly/release
pathway that predominates under these experimental conditions.
Clarification of these hypotheses requires more insights into the
mechanisms of HCV particle assembly and release.
Although extensive tests with other HCV isolates have not been
performed we hypothesize that non-adapted consensus genomes, at
least those with proven in vivo infectivity, will also support
production of infectious virus particles in transfected Huh-7 cells.
However, owing to the very low replication levels of these genomes,
demonstration of infection of cell cultures will be very difficult, even
when stimulating replication e.g. by kinase inhibitors. As shown
here, inoculation of xenografted mice with cell culture grown HCV
particles is an alternative that is more robust and reliable. In fact,
infection of uPA-SCID mice with supernatants of Con1/wt or
Con1/K1846T transfected cells resulted in a well detectable
viremia. In contrast, supernatants of Con1/NS3+K1846T trans-
fected cells turned out to be non-infectious although these
supernatants also contained viral RNA and low amounts of core
protein. The nature of these RNA/core structures is not known but
due to their low abundance they are not amenable to a biophysical
characterization. They may correspond to lipid-containing replica-
tion complexes that were released from dying cells, similar to what
we and others described earlier [25,44].
For several positive strand RNA viruses it has been shown that
RNA translation, replication and assembly are tightly coupled [54–
57]. This coupling may act as a proof-reading mechanism to
exclude from progeny particles those viral genomes that have a
defect in either translation or RNA replication. As shown here a
HCV genome that is unable to replicate (Con1/D318N; Fig. 1) still
releases core protein to an amount comparable to the wild type.
Although formal proof is missing that this core protein indeed
corresponds to virus particles, our data suggest that HCV particle
assembly may occur even in the absence of RNA replication.
In summary we demonstrate the production of infectious HCV
particles in the Huh-7 cell line upon transfection with the genotype
1b isolate Con1. The interference of REMs with the assembly
process provides an explanation why earlier attempts to produce
infectious HCV in cell culture were of very limited success.
Although this hurdle has in principle been overcome with the
identification of the JFH-1 isolate, more replication and assembly
competent HCV isolates are urgently needed to cover the full
spectrum of genotypes, especially those that are poorly accessible
to antiviral therapy. The observation that infectious HCV particles
can be produced in Huh-7 cells by the genotype 1b isolate Con1
may provide a new starting point that likely can be extrapolated to
other isolates with proven in vivo infectivity.
Materials and Methods
Cell culture
Huh-7 cell clones Huh7-Lunet [58] and Huh7.5 [42] that both
are highly permissive for HCV RNA replication were used for
electroporation and infection assays. Cells monolayers were grown
in Dulbecco’s Modified Eagle Medium ([DMEM] Life Technol-
ogies GmbH, Karlsruhe, Germany) supplemented with 2 mM L-
glutamine, nonessential amino acids, 100 U of penicillin per ml,
100 mg of streptomycin per ml, and 10% fetal calf serum (complete
DMEM). Cells were routinely subpassaged twice a week at a ratio
of 1:4 to 1:10, depending on confluency. For infection experi-
ments, Huh7.5 cells were seeded 24 h prior to infection into 12-
well plates or on glass cover-slips contained in 24-well plates. Cell
densities ranged from 2 to 5610
4 cells per well in case of a 12-well
plate and 1 to 3610
4 cells per well in case of a 24-well plate.
Plasmid construction
All full-length HCV Con1 constructs are based on the consensus
clone of the HCV isolate Con1 [59] [AJ238799]. Generation of pFK-
Con1/NS3+S2197P, pFK-Con1/NS5A and pFK-Con1/D318N
(Con1/D318N) has been described recently [27]. Plasmid pFK-
Con1/NS3+S2197P differs from pFK-Con1 by 5 nucleotide
exchanges (A3946G, C4180T, C6842T, C6926T, and T6930C).
Three of these mutations cause amino acid substitutions (E1202G,
T1280I and S2197P), whereas the remaining changes are silent.
Construct pFK-Con1/NS5A contains a single amino acid substitu-
tion (S2197P) and two silent nucleotide changes (C6842T and
C6926T). The pFK-Con1/D318N plasmid encodes a replication-
deficient variant of Con1 that carries a single amino acid substitution
changing the GDD motif of the NS5B polymerase to D318N [15].
Constructs pFK-Con1/DE1-E2, pFK-Con1/A358ins and pFK-
Con1/NK367AA were generated by PCR-based mutagenesis of
pFK-Con1. PFK-Con1/DE1-E2 carries an in frame deletion
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and E2 coding region. Construct pFK-Con1/A358ins encodes a
Con1genomewithaninsertionofanalanineresidueafteraminoacid
358 which is located in the transmembrane domain of E1. This
mutation was shown to abrogate heterodimerization of E1 and E2
[31]. Variant pFK-Con1/NK367AA comprises two mutations in the
transmembrane region of E1, replacing asparagines 367 and lysine
370 by alanine residues. Similar to A358ins, also this mutant was
shown to abrogate heterodimerization of HCV glycoproteins [30].
Constructs pFK-Con1/K1846T and pFK-Con1/NS3+K1846T
were generated by insertion of a SfiI-SfiI HCV genome fragment
isolated from pFK-I341Luc/NS3-39/K1846T and pFK-I341Luc/
NS3-39/ET [17]. Constructs pFK-Con1/NK367AA+K1846T and
pFK-Con1/A358ins+K1846T were generated by insertion of a SfiI-
SfiI HCV genome fragment isolated from pFK-Con1-K1846T.
Generation of subgenomic replicons pFK-I389Luc/NS3-39/wt and
pFK-I389Luc/NS3-39/GND has been already described [15].
Plasmids pFK-I389Luc/NS3-39/K1846T and pFK-I389Luc/NS3-
39/NS3+K1846T were generated as described above by transfer of a
SfiI-SfiI HCV genome fragment. Allmutations were verified by DNA
sequence analysis. The exact cloning strategies used to generate these
constructs can be obtained upon request.
In vitro transcription
PFK-based plasmids were restricted wit AseI and ScaI, whereas
puC-based plasmids were linearized with XbaI. Digested plasmids
were extracted with phenol and chloroform, ethanol precipitated
and dissolved in RNase-free water. In vitro transcription mixtures
comprised 80 mM HEPES [pH7.5], 12 mM MgCl2,2 m M
spermidine, 40 mM dithiothreitol (DTT), each nucleotide triphos-
phate at a concentration of 3.125 mM, 1 U RNasin/ml of reaction
volume, 0.1 mg restricted plasmid DNA/ml, and 0.6 U of T7 RNA
polymerase/ml. Reactions were incubated for 2 h at 37uC, an
additional 0.3 U T7 RNA polymerase/ml was added and the
mixture as incubated another 2 h. Transcription was terminated
by addition of 1.2 U of RNase free DNase (Promega) per mgo f
plasmid DNA and incubation for 30 min at 37uC. After extraction
with acidic phenol and chloroform, RNA was precipitated with
isopropanol and dissolved in RNase-free water. RNA concentra-
tion was determined by measuring absorbance at 260 nm, and the
integrity of the transcripts was verified by denaturing formalde-
hyde agarose gel electrophoresis.
Electroporation of Huh-7 cells and transient HCV
replication assays
Single cell suspensions of Huh-7, Huh7-Lunet and Huh7.5 cells
were prepared by trypsinization of monolayers. Detached cells
were washed once with PBS and resuspended in cytomix [60]
containing 2 mM ATP and 5 mM glutathione at a concentration
of 1.5610
7 cells per ml in case of Huh7.5 cells or 1610
7 cells per
ml in case of Huh-7 and Huh7-Lunet cells. Ten mgo fin vitro
transcript was mixed with 400 ml of the cell suspension, and
electroporated at 960 mF and 270 V by using a Gene Pulser
system (Bio-Rad, Munich, Germany) and a cuvette with a gap
width of 0.4 cm (Bio-Rad). Depending on the amount of
transfected cells required for the respective experiment either a
single electroporation was performed, or cells from several
electroporations were pooled and seeded into culture dishes.
Preparation of total RNA and Northern blot analysis
Total cellular RNA for Northern blots was prepared by a single-
step isolation method [61]. For RNA detection by quantitative
PCR, the NucleoSpin RNAII kit (Macherey-Nagel, Du ¨ren,
Germany) was employed and used according to the instructions
of the manufacturer. For Northern blotting, total cellular RNA
was denatured by treatment with 5.9% glyoxal in 50%
dimethylsulfoxide and 10 mM sodium phosphate buffer
[pH 7.0] at 50uC for 1 h. Subsequently, RNA was resolved by
denaturing agarose gel electrophoresis and transferred to a
positively charged nylon membrane (Hybond-N+; Amersham
Pharmacia Biotech, Freiburg, Germany) with 50 mM NaOH
using a vacuum manifold. After drying and crosslinking by UV
irradiation, hybridization was performed according to standard
protocols [62]. HCV-specific RNA was detected using a [
32P]-
labeled negative sense riboprobe complementary to NS5B and the
39 UTR (nucleotides 8374–9440). HCV-specific bands were
quantified by phosphimaging using a BAS 2500 scanner from Fuji.
Quantitative detection of HCV core by ELISA and HCV
RNA by PCR
HCV core protein expressed within cells or secreted into the
culture medium was quantified using the commercially available
Trak C Core ELISA (Ortho Clinical Diagnostics, Neckargemu ¨nd,
Germany) according to the instructions of the manufacturer.
When intracellular core expression was determined, cells were
lysed in ice cold PBS supplemented with 1% Triton-X-100, 1 mM
PMSF and 0.1 mg/ml Aprotinin. Lysates were cleared at
20,0006g for 10 min. and supernatants were measured at a
dilution of 1:50 (or higher) in PBS. Cell culture medium was
filtered through 0.45 mm pore size filters and either directly used
for ELISA or diluted with PBS prior to measurement.
Quantitative detection of HCV RNA by qRT-PCR
Total RNA prepared from gradient fractions, infected cells or
magnetic beads was eluted from NucleoSpin RNAII columns in a
volume of 40 ml RNase-free water. Five microliters of the
respective sample were used for quantitative RT-PCR analysis
employing an ABI PRISM 7000 Sequence Detector (Taqman;
Perkin-Elmer). Amplifications were conducted at least in duplicate
with the One Step RT-PCR Kit (Qiagen, Hilden, Germany) using
the following primers and 39-phosphate-blocked, 6-carboxyfluor-
escine (6-FAM)- and tetrachloro-6-carboxyfluorescine (TAMRA)-
labeled probes (TIB Molbiol, Berlin, Germany): HCV-Con1
Taqman probe, 59-6FAM-TCC TGG AGG CTG CAC GAC
ACT CAT-TAMRA-39; HCV-Con1-S66, 59-ACG CAG AAA
GCG TCT AGC CAT-39; and HCV-Con1-A165, 59-TAC TCA
CCG GTT CCG CAG A-39; HCV-JFH1 Taqman probe,; HCV-
JFH1-S147, 59-TCT GCG GAA CCG GTG AGT A-39; HCV-
JFH1-A221, 59-GGG CAT AGA GTG GGT TTA TCC A-39.
Reactions were carried out in three stages under the following
conditions: stage 1, 60 min at 50uC (reverse transcription
reaction); stage 2, 15 min at 95uC (heat inactivation of reverse
transcriptase and activation of Taq polymerase); stage 3, 40 cycles,
with 1 cycle consisting of 15 sec at 95uC and 1 min at 60uC. The
total reaction volume was 15 ml and contained the following
components: 2.66 mM 6-carboxy-X-rhodamine (Rox, passive
reference), 4 mM MgCl2, 0.66 mM deoxynucleoside triphos-
phates, 0.266 mM probe, 1 mM (each) sense and antisense primer,
and 0.6 ml of enzyme mix. The amounts of HCV RNA were
calculated by comparison to serially diluted in vitro transcripts
included in the qRT-PCR analysis.
Ultracentrifugation
About 20 to 30 ml of filtered cell culture medium derived from
Huh-7 cells 24 h or 72 h post transfection were concentrated via
ultracentrifugation over a 40% or 60% (wt/vol) iodixanol
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(r=1.215 g/ml, or 1.320 g/ml respectively), prepared in CSM
(0.85% [wt/vol] NaCl, 10 mM Tricine-NaOH [pH 7.4];
r=1,006 g/ml), in a SW28 rotor for 7 h at 100,0006g (RCFavg)
at 4uC. Density cushion and interface were resuspended and used
for infection or virus capture assays. Alternatively, resuspended
material was transferred to the bottom of a fresh tube, and overlaid
with a linear iodixanol gradient (60% to 0%) and spun for 18 h in
a SW41 rotor at 110,0006g (RCFavg)a t4 uC. Twelve fractions
(1 ml each) were harvested from the top. The amount of HCV
core protein in 100 ml of each fraction was determined by using
Trak C ELISA. For quantifying HCV RNA, 100 ml of the
respective gradient fraction were used for RNA preparation with
the NucleoSpin RNAII kit (Macherey-Nagel, Du ¨ren, Germany).
Five ml of the eluate (equivalent to 12.5% of the sample) were used
for quantitative RT-PCR.
Virus capture assay
For the production of lentiviral HCV pseudoparticles (HCVpp),
293T cells were transfected by using the calcium phosphate
method essentially as described. Briefly, 2.5610
6 293T cells were
seeded in 10-cm diameter plates 1 day before transfection with
2.7 mg of phCMVDCE1-E2(Con1), 8.1 mg of HIV-Gag-Pol
expression construct [pCMV_R8.74 [63]], and 8.1 mg of the
lentiviral vector pHR9-CMV-GFP [64] (where CMV is cytomeg-
alovirus and GFP is green fluorescent protein). The medium was
replaced 8 h after transfection. Supernatants containing the
pseudo-particles were harvested 48 h later, cleared by passage
through 0.45-mm-pore-size filters. Cleared HCVpp-containing
culture fluids were used for immuno-capture assays. The
equivalent of 25 ml of Dynabeads Protein A (Dynal, Invitrogen)
slurry were washed according to the instructions of the
manufacturer and coupled to 4 mg of human monoclonal antibody
by continuous shaking at room temperature in a total volume of
25 ml sodium phosphate buffer [pH 8.1] for 40 min. Beads were
washed 3 times with 0.5 ml sodium phosphate buffer and blocked
1 h at room temperature with 200 ml PBS, 2% bovine serum
albumin. After 3 washes with PBS, beads were incubated with
100 ml filtered supernatant containing HCVpp for 1 h at 4uCb y
shaking, washed 5 times with PBS and resuspended in a final
volume of 100 ml PBS. Bound p24 on the beads was measured by
using the INNOTEST HIV Antigen mAb kit (Innogenetics) with
minor modification of the protocol. In brief, beads were incubated
with 100 ml conjugate buffer 1 to release bound p24 and
centrifuged 1 min at 14,000 rpm. Supernatant was diluted 1:50
into conjugate buffer 1 and further processed according to the
standard protocol of the supplier. Human monoclonal antibodies
employed for virus capture assays were described previously [65].
For capture of cell culture derived HCV Con1 particles, 5 mgo f
purified human monoclonal antibodies (CBH5, or the negative
control RO4 antibody) coupled to protein A magnetic beads
(Dynal) were incubated with filtered and concentrated cell culture
medium for 1 h using an overhead rotor at 4uC. Beads were
washed 5 times with 1 ml PBS, and RNA was extracted by using
the NucleoSpin RNAII kit (Macherey-Nagel). Captured RNA was
quantified by using TaqMan qRT-PCR.
Characterization of virus particles by detergent and
nuclease treatment
Virus particles contained in culture supernatant were concen-
trated as described above. For each capture assay 5 mg of CBH5
or RO4 antibody was covalently coupled to tosyl-activated
Dynabeads (Invitrogen, Germany) according to the instructions
of the manufacturer. Virus particles were captured as described
above, beads were washed 5-times with 1ml of PBS supplemented
with 1 mM CaCl2 and resuspended in 100 ml of the same buffer.
Immune complexes were left untreated or incubated with 0.5%
Triton X-100 for 5 min at RT in the presence or absence of 2.5 ml
RNAsin (Promega, Mannhein, Germany). Thereafter, beads were
incubated in the absence or presence of 2U S7 nuclease (Roche
Mannheim, Germany) for 30 min at 37uC and the nuclease was
inactivated by the addition of 2 mM EDTA. RNA was extracted
by using the NucleoSpin RNAII kit (Macherey-Nagel, Du ¨ren,
Germany) and RNA was quantified by using TaqMan qRT-PCR.
Replication assays in the presence of casein kinase I
inhibitor H479
Transient HCV RNA replication assays were performed as
described previously above. Huh7.5 cells were electroporated with
a subgenomic Con1/wt or Con1/K1846T or Con1/D318N or
Con1/NS3+K1846T luciferase replicon and resuspended in 20 ml
culture medium. Aliquots of 2 ml each were seeded per well of a 6-
well plate and replication was determined by measuring luciferase
activity 4, 24, and 48 h post-transfection. Four hours after
electroporation, medium was removed and cells were treated with
various concentrations of H479. Luciferase activities were
normalized to the DMSO control value to determine the fold
induction of replication. Statistical analyses were conducted using
PRISM4 (GraphPad Software Inc.) and two-way ANOVA test.
Production of concentrated culture supernatants, cell
culture infectivity assay and immunofluorescence
Supernatants from 10 electroporations of Huh7.5 cells with each
10 mg Con1/wt or Con1/K1846T or Con1/NS3+K1846T were
harvested 12 and 24 h post electroporation and pools were filtered
through 0.45 mm-pore-size filters. Filtrates were loaded onto a
cushion composed of 4 ml 10% Optiprep-PBS and 3 ml 28%
Optiprep diluted in serum-free-medium. Samples were centrifuged
for 4 h at 100,0006g in a SW28 rotor (Beckman) at 4uC. Virus
concentrated at the interface of the cushion was recovered and
concentrated by centrifugation using a Centricon Plus-70 centrif-
ugal filter device (100K NMWL; Millipore, Germany) according to
the instructions of the manufacturer. Concentrated virus was
resuspended in 1 ml culture medium. Based on core-ELISA
measurements we calculated that about 50% of core protein was
recovered in this final preparation and that core protein was
concentrated 200-fold. Huh7.5 cells seeded on glass cover slips were
pretreated with or without 25 nM of Concanamycin A for 1 h at
37uC;thereaftercellswereinfected with 300 mlofthe concentrate in
the presence or absence of 25 nM Concanamycin A (Sigma). Four
hours later cells were washed with fresh medium and incubated in
complete medium with or without H479 (10 mM). After 72 h, cells
were fixed with icecold methanol. Immunolabelling of NS5A was
performed with a monoclonal antibody specific for NS5A (Virostat,
Portland, USA) at a dilution of 1:50 in PBS supplemented with 5%
normal goat serum. NS3 was detected with a rabbit polyclonal
antiserum obtained by immunization with a recombinant NS3
fragment of JFH-1 (amino acid residues 293 to 631). Bound primary
antibodies were detected by using a goat antibody conjugated to
AlexaFluor488 (Invitrogen, Germany) at a dilution of 1:1,000 in
PBS/5% normal goat serum. Nuclear DNA was counterstained
with DAPI (Molecular Probes, Eugene, OR). Images were acquired
with an inverted fluorescence microscope (Leica, Germany).
Infection of uPA+/+-SCID mice
The mouse study was conducted at the Ghent University
Hospital, with protocols approved by the Ethical Committee and
HCV Particle Production and Infectivity
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Medicine. Transgenic SCID mice overexpressing the uPA gene
under the control of an albumin promoter (uPA
+/+-SCID) were
xenografted with primary human hepatocytes as described
elsewhere [66]. Chimeric mice were inoculated by intraperitoneal
injection of 100 ml of purified and concentrated culture superna-
tant (prepared as described above). Inocula contained 2610
8 IU
HCV RNA for each preparation and 540 pg core protein for
Con1/wt, 200 pg for Con1/K1846T and 23 pg core protein for
Con1/NS3+K1846T. EDTA plasma samples were collected at
weekly intervals after inoculation and infection was monitored by a
commercial qRT-PCR kit (Roche COBAS AmpliPrep/Taq-
Man48 assay, Roche Diagnostics). Due to dilution of the samples,
the detection limit of the test was 750 IU/ml.
Preparation of total RNA from mouse serum,
amplification of HCV RNA by RT-PCR and sequence
analysis of cloned amplicons
HCV RNA was isolated from 110 ml of serum taken from
mouse K831 six weeks post inoculation with Con1/K1846T. Viral
RNA was isolated by using the Nucleo Spin RNA Virus Kit
(Macherey-Nagel, Germany) as recommended by the manufac-
turer. RT-PCR was performed with the Expand-RT system
(Roche, Germany) according to the instructions of the manufac-
turer using primer A-9413 (59-CAG GAT GGC CTA TTG GCC
TGG AG-39) for cDNA synthesis. First amplification was done by
using the Expand Long Template PCR Kit (Roche) and primers
S-4542 (59-GAT GAG CTC GCC GCG AAG CTG TCC-39) and
A-6156 (59-CGC TCT CAG GCA CAT AGT GCG TGG-39).
Because of low RNA levels nested PCR was required, for which we
used primers S-4542 and A-6103 (59-GCT ATC AGC CGG TTC
ATC CAC TGC-39). Amplified fragment was inserted into pFK-
I389Luc-EI/NS3-39/JFH1-dg after restriction with NsiI and HpaI.
Sequence analysis was performed using primer A-8242 (59- CGT
TGG GCA GGG GAG TAC TGG AAG -39).
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